Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Double-blind randomized placebo-controlled phase 2 study of AMG 145 in heterozygous familial hypercholesterolemia
2011-001528-39Phase 2Completed
- Sponsor
- Amgen
- Start
- May 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) comparing AMG 145 arm with Placebo arm (2 arms). Primary endpoint: Percent change from baseline in LDL-C at week 12. Started May 2011; status: completed.
02
Drugs
evolocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)
Beyond the preview
Go deeper on 2011-001528-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-001528-39.